Correction: Trials 23, 583 (2022)
https://doi.org/10.1186/s13063-022-06533-0
The original publication of this article [1] erroneously contained "2X2 design" in the title whilst the study itself did not include a 2 × 2 design. The original article has been updated.
Contributor Information
Tania A. Smith, Email: tania.smith@cinvestav.mx
Carlos Hoyo-Vadillo, Email: citocromo@cinvestav.mx.
Akosua Agyeman Adom, Email: akosua.agyeman@ucl.ac.uk.
Liliana Favari-Perozzi, Email: lfavari@cinvestav.mx.
Silke Gastine, Email: s.gastine@ucl.ac.uk.
Hakim-Moulay Dehbi, Email: h.dehbi@ucl.ac.uk.
Beatriz Villegas-Lara, Email: beatrizvillegaslara@gmail.com.
Eduardo Mateos, Email: infectologia21@hotmail.com.
Yessica Sara Pérez González, Email: draperez_medinfection@yahoo.com.mx.
Maria D. Navarro-Gualito, Email: cacahuatesparaloscuates@hotmail.com
Alejandra S. Cruz-Carbajal, Email: fany-alito@hotmail.com
Miguel A. Cortes-Vazquez, Email: mikeunam@icloud.com
Carolina Bekker-Méndez, Email: bekkermendez@yahoo.com.
Charmina Aguirre-Alvarado, Email: charmina_burana@yahoo.com.mx.
Gisela Aguirre-Gil, Email: gisi@hakkenenterprise.com.
Lucero Delgado-Pastelin, Email: ludelgado@hakkenenterprise.com.
Andrew Owen, Email: aowen@liverpool.ac.uk.
David Lowe, Email: d.lowe@ucl.ac.uk.
Joseph Standing, Email: j.standing@ucl.ac.uk.
Jorge Escobedo, Email: jorgeep@unam.mx.
Reference
- 1.Smith T, et al. Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE) Trials. 2022;23:583. doi: 10.1186/s13063-022-06533-0. [DOI] [PMC free article] [PubMed] [Google Scholar]